Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesMylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationHuman leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.A continuous assay for DNA cleavage: the application of "break lights" to enediynes, iron-dependent agents, and nucleasesEmerging treatments in acute myeloid leukaemia.Expression of leukemia-associated antigen, JL1, in bone marrow and thymus.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyChemical approaches to the discovery and development of cancer therapies.CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives.The role of gemtuzumab ozogamicin in acute leukaemia therapy.New considerations in the design of clinical trials for the treatment of acute leukemia.Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyDecitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsThe clinical and therapeutic implications of cancer stem cell biology.Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.The discovery of medicines for rare diseasesIntravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.Treatment of relapsed acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.Adaptive decision making in a lymphocyte infusion trial.Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association
P2860
Q26800175-8557D988-A950-42F5-8919-E806EC4EDCDDQ28071384-6628C430-9122-481E-9356-48899263999AQ28207989-E7E798C2-98FA-474D-972F-C0911FDAAFE4Q34451956-B05E6F7E-6B8F-4C24-AE26-9CF5A8EA5A73Q35567329-BD3B2708-7EF2-49F9-BB09-B414CA0F869EQ35779278-3738F879-9829-4185-B436-180D4057FCB9Q35842009-345C02C7-0D5D-4B15-B66D-3CF1CF5E2DB0Q35980938-D8565FC1-BBEA-4B03-A886-90D91A6CDAE2Q36058588-50930A20-F084-49AA-8746-95BFEBF8388DQ36085630-6D3900C4-F209-45D9-AA10-FCCF392D21DCQ36221544-8E3802F4-D88E-43B5-AB4F-D76E4AA5B997Q36367816-FF5BBBCE-675F-439A-81F5-C15DFC8C167CQ36641721-2CB6ADFC-8474-4BF9-8AD0-852B0F5CD4F0Q36698173-42A2EDC5-47B4-47AF-9DBD-73D15137F4D9Q36989586-827727D3-6720-49CD-B2D3-4087777794DDQ37909375-72169DB1-ED22-47FB-9CF4-60083CA27705Q38235929-5DCB7289-7234-4A21-905E-8A22C58EE921Q39152821-F6BA5CA3-9B02-46AD-9A8F-89EA9713BFD2Q40552183-8095AF30-EAC9-40E4-8073-CA9C621FA1F4Q40616812-9D9DAFE4-E7CF-42F5-8E74-72378C020C3BQ40677793-DA5ED35E-6518-46BC-A964-88F55FB3570AQ43195338-CE84ADA9-D07C-49ED-9F53-2B39D0527570Q52032741-75942D46-68F3-41B2-B531-2ECCD1E95824Q52640199-6D2DBD14-00FB-4C38-9668-FCEAAD7DED8FQ58415977-382D5550-3B68-4D9A-AD3B-77EE985DCDDD
P2860
Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@ast
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@en
type
label
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@ast
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@en
prefLabel
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@ast
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@en
P356
P1433
P1476
Monoclonal antibodies to the m ...... ibody calicheamicin conjugate.
@en
P2093
I D Bernstein
P2888
P304
P356
10.1038/SJ.LEU.2401663
P577
2000-03-01T00:00:00Z
P5875
P6179
1034642853